Abstract
Bergamottin (BG), a component of grapefruit juice, is a mechanism-based inactivator of cytochromes P450 (P450) 2B6 and 3A5 in the reconstituted system. The inactivation of both P450s was NADPH-dependent and irreversible. The kinetic constants for the inactivation of the 7-ethoxy-4-(trifluoromethyl)coumarin O-deethylation activity of P450 2B6 were: KI, 5 μM; kinact 0.09 min–1; and t1/2, 8 min. The kinetic constants obtained for the inactivation of the testosterone 6β-hydroxylation activity of P450 3A5 were: KI, 20 μM; kinact 0.045 min–1; and t1/2, 15 min. Incubations of P450s 2B6 and 3A5 with 20 μM BG at 37°C for 20 min resulted in an ∼60% loss in the catalytic activity that was accompanied by a significant loss in intact heme and a similar decrease in the reduced CO difference spectrum. The extrapolated partition ratios for BG with P450s 2B6 and 3A5 were ∼2 and ∼20, respectively. Liquid chromatography-mass spectroscopy analysis of the BG-inactivated samples showed that the mass of the inactivated apoprotein had increased by approximately 388 Da for both P450 2B6 and P450 3A5. SDS-polyacrylamide gel electrophoresis analysis demonstrated that [14C]BG was irreversibly bound to the apoprotein in the BG-inactivated samples. The stoichiometry of binding was ∼0.5 mol BG metabolite/mol of each P450 inactivated. High-pressure liquid chromatography analysis of the metabolites of BG showed that P450 2B6 generated two major metabolites, whereas P450 3A5 generated three additional metabolites. Two of metabolites were identified as 6′,7′-dihydroxybergamottin and bergaptol.
Footnotes
-
This work was supported in part by National Institutes of Health Grant CA16954.
-
doi:10.1124/jpet.104.079608.
-
ABBREVIATIONS: P450, cytochrome P450; BG, bergamottin; DHBG, 6′,7′-dihydroxybergamottin; GSH, glutathione; EFC, 7-ethoxy-4-(trifluoromethyl)coumarin; b5, cytochrome b5; HPLC, high-pressure liquid chromatography; PAGE, polyacrylamide gel electrophoresis; ESI, electrospray ionization; LC, liquid chromatography; MS, mass spectroscopy; L-754,394, N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide.
- Received October 21, 2004.
- Accepted December 15, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|